Rituximab in kidney disease and transplant

Rituximab is a chimeric monoclonal antibody that binds to CD20 antigen of B‐cells. It depletes the level of mature B‐cells by various mechanisms such as mediation of antibody‐dependent cellular cytotoxicity, complement‐dependent cytotoxicity, and B‐cell apoptosis. Rituximab is a USFDA approved drug...

Full description

Saved in:
Bibliographic Details
Published in:Animal models and experimental medicine 2019-06, Vol.2 (2), p.76-82
Main Authors: Chauhan, Kajal, Mehta, Anita A.
Format: Article
Language:English
Subjects:
Antigens
Apoptosis
Biopsy
CD20 antigen
Chronic lymphocytic leukemia
Clinical trials
Cytotoxicity
Granulomatosis
Immunotherapy
Kidney diseases
Kidney transplantation
Long-term effects
Lupus
Lymphatic leukemia
Lymphocytes B
Lymphocytes T
Lymphoma
Monoclonal antibodies
Pemphigus
Proteins
renal diseases
renal transplant
Review
Rheumatoid arthritis
Rituximab
Targeted cancer therapy
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rituximab is a chimeric monoclonal antibody that binds to CD20 antigen of B‐cells. It depletes the level of mature B‐cells by various mechanisms such as mediation of antibody‐dependent cellular cytotoxicity, complement‐dependent cytotoxicity, and B‐cell apoptosis. Rituximab is a USFDA approved drug for clinical use in non‐Hodgkin's B‐cell lymphoma (NHL), rheumatoid arthritis, chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis and pemphigus vulgaris. It is also known for its “off label” use in renal disease and renal transplant worldwide. However, the exact mechanisms by which it exerts its effect in the aforementioned condition remain unclear but may be related to its long‐term effects on plasma cell development and the impact on B‐cell modulation of T cell responses. This review discusses the current use of rituximab in renal disease and renal transplantation, and its potential role in novel therapeutic protocols.
ISSN:2576-2095
2096-5451
2576-2095
DOI:10.1002/ame2.12064